© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Health and Biotech

Top Section/Ad

Top Section/Ad

Most recent


Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
◆ Single digit premiums offered ◆ Reverse Yankees dominating euro supply ◆ Floaters proving popular with multi-tranche issuers
More articles/Ad

More articles/Ad

More articles

  • CEE
    Turkey has joined the list of emerging market countries experimenting with quantitative easing programmes in the wake of the Covid-19 crisis engulfing conventional funding markets.
  • JP Morgan’s chief investment office is likely to be the main anchor buyer in the £1.29bn senior tranche of a new UK RMBS, the second slug of a portfolio sold by the UK government’s bad bank last year. The deal, officially priced on Tuesday, was executed at levels determined before the coronavirus panic blew out spreads for UK mortgage bonds.
  • London-listed Russian steel firm Evraz has raised a syndicated loan with lenders honouring the pricing terms agreed before the outbreak of coronavirus that has wreaked havoc in markets.
  • Italy’s borrowing is set to increase as it attempts to weather the economic impact of coronavirus. But Davide Iacovoni, director general of the Italian public debt office, told GlobalCapital that he did not expect investors to abandon the country’s debt. He also called for some form of European risk sharing.
  • Equity capital markets are slowly reopening for companies at a time when there is a dire need for funding. However, the Covid-19 sell-off in global stock markets in the past month has meant that funds and asset managers have had limited inflows, meaning they have less cash to use in new deals. This is leading to a higher degree of selectivity.
  • Some of the largest financial institutions in the eurozone have yet to cancel or postpone their dividend distributions for this year, despite explicit guidance from the European Central Bank urging them to restrict payouts during the coronavirus crisis.